News Releases

07/11/24
Ryvu Therapeutics Reports 2024 Q3 Financial Results and Provides Corporate Update
Read more
29/10/24
Ryvu Therapeutics to Collaborate with nCage Therapeutics on the Development of a Next-Generation ADC Platform
Read more
23/10/24
Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium
Read more
09/10/24
Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium
Read more
23/09/24
Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit
Read more
19/09/24
Ryvu Therapeutics Announces Dosing of the First Patient in the REMARK Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Read more
11/09/24
Ryvu Therapeutics Reports 2024 Half-Year Financial Results and Provides Corporate Update
Read more
14/06/24
Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress
Read more
15/05/24
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
Read more
14/05/24
Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress
Read more
10/04/24
Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
Read more
13/03/24
Ryvu Therapeutics Summarizes 2023 Fiscal Year and Provides Corporate Update
Read more
06/03/24
Ryvu Therapeutics Announces Disbursement of First Tranche of EUR 8 Million Venture Debt from the European Investment Bank  
Read more
06/03/24
Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
Read more
14/02/24
Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS
Read more
31/01/24
Ryvu Announces Dosing of the First Patient in the RIVER-81 Phase II Study of RVU120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory AML
Read more
04/01/24
Ryvu Therapeutics participates in the upcoming 13th Annual LifeSci Partners Corporate Access Event
Read more
11/12/23
Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting
Read more
07/12/23
Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023
Read more
29/11/23
Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Read more
02/11/23
Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting
Read more
23/10/23
Ryvu Therapeutics provides an update on the progress of RVU120 Phase I studies in patients with solid tumors and AML/HR-MDS, and presents the updated development plan for RVU120
Read more
20/10/23
Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes (LR-MDS)
Read more
16/10/23
Ryvu Therapeutics Presents Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Read more
04/10/23
Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Read more
14/09/23
Ryvu Therapeutics’ Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL)
Read more
13/09/23
Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update
Read more
11/09/23
Ryvu Therapeutics to Participate in the 31st Congress of the Polish Society of Hematology and Transfusion Medicine
Read more
04/08/23
Ryvu Therapeutics Announces Signing Two Agreements with Fortrea to Operationally Execute Phase II Clinical Trials of RVU120 in Hematology
Read more
31/07/23
Ryvu Therapeutics enters into a PLN 62.3 million financing agreement with the Medical Research Agency to conduct a Phase II clinical trial of RVU120 in combination therapy
Read more
31/07/23
Ryvu Therapeutics Announces Entering into Agreement in the Area of Securing Venetoclax Supply Chain for RVU120 Phase II Clinical Trial in Combination Therapy in Hematology
Read more
14/07/23
Ryvu Therapeutics enters into two agreements with Clinscience, part of the NEUCA Group, in the area of data management and biostatistics for RVU120 Phase II clinical trials in hematology
Read more
06/07/23
Ryvu Therapeutics enters into two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials
Read more
09/06/23
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress
Read more
16/05/23
Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Read more
11/05/23
Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress
Read more
24/03/23
Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Read more
15/03/23
Ryvu Therapeutics Named the Stock Exchange Company of the Year
Read more
05/01/23
Ryvu Therapeutics to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel and 12th Annual LifeSci Partners Corporate Access Event
Read more
22/12/22
Ryvu Therapeutics announces closing of equity offering with gross proceeds over PLN 250 million
Read more
11/12/22
Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting
Read more
08/12/22
Ryvu Therapeutics initiates public offering of shares
Read more
30/11/22
BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno Modulatory Small Molecule Candidates
Read more
23/11/22
Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Read more
03/11/22
Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting
Read more
26/10/22
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
Read more
12/10/22
Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
Read more
28/09/22
Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update
Read more
19/08/22
Ryvu Therapeutics presents its Development Plans for 2022-2024, aims to accelerate its mission
Read more
17/08/22
EIB to support Ryvu Therapeutics’ discovery, research and development of new cancer treatments with €22 million
Read more
26/07/22
Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board
Read more
07/07/22
Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
Read more
10/06/22
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress
Read more
06/06/22
Ryvu Therapeutics to Host Key Opinion Leader Webinar on RVU120 for the Treatment of Hematological Malignancies and Solid Tumors
Read more
19/05/22
Ryvu Therapeutics to Participate in Upcoming Investor Conferences
Read more
18/05/22
Ryvu Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Read more
12/05/22
Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association Congress. Partner Menarini Group to present clinical poster on SEL24 (MEN1703).
Read more
27/04/22
Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Read more
11/04/22
Ryvu Therapeutics Announces Presentations at the AACR 2022 Annual Meeting
Read more
15/03/22
Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Read more
08/03/22
Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting
Read more
17/01/22
Ryvu Therapeutics appoints Hendrik Nogai, M.D. as Chief Medical Officer
Read more
03/01/22
Ryvu Therapeutics to participate in the LifeSci Partners 11th Annual Corporate Access Event and H.C. Wainwright Bioconnect Conference
Read more
14/12/21
Ryvu announces option to license inflammation program exercised by Galapagos NV
Read more
13/12/21
Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology Annual Meeting and the 44th San Antonio Breast Cancer Symposium
Read more
10/11/21
Ryvu Therapeutics Reports Q3 2021 Financial Results
Read more
09/11/21
Ryvu Therapeutics to Highlight HPK1 and STING Programs at the Upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Read more
04/11/21
Ryvu Therapeutics & Collaborators to Present Clinical and Translational Data from RVU120 and SEL24/MEN1703 at the 63rd ASH Annual Meeting & Exposition and the 44th Annual SABCS
Read more
07/10/21
Ryvu Therapeutics co-runs Drug Discovery and Development MSc degree, at the Faculty of Pharmacy, Jagiellonian University
Read more
08/09/21
Ryvu Therapeutics Reports 2021 Half-Year Financial Results
Read more
25/08/21
Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors and CMO Transition
Read more
18/08/21
Ryvu Therapeutics publishes MCT4 inhibitors research paper in the Journal of Medicinal Chemistry
Read more
03/08/21
Ryvu Therapeutics to participate in upcoming global investor conferences
Read more
14/07/21
FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Read more
11/06/21
Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual EHA Congress. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini.
Read more
10/06/21
Representatives of the Ministry of Economic Development, Labour and Technology visited Ryvu Therapeutics
Read more
10/06/21
Ryvu Therapeutics among the founding members of 30% Club Poland
Read more
09/06/21
Discussion On Ryvu Data Presented at EHA 2021 – Conference Call
Read more
02/06/21
Synthetic lethality in cancer treatment – Ryvu Therapeutics seminar
Read more
01/06/21
SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021
Read more
28/05/21
Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland
Read more
18/05/21
Ryvu Therapeutics announces participation in the UBS 2021 Global Healthcare Virtual Conference and the Erste Group Innovation Conference 2021
Read more
14/05/21
Ryvu Therapeutics presents at STING- & TLR-Targeting Therapies Summit
Read more
12/05/21
Ryvu Therapeutics to Present Clinical and Translational Data from RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. New clinical abstract on SEL24(MEN1703) also available.
Read more
12/05/21
Ryvu Therapeutics Reports First Quarter 2021 Financial Results
Read more
26/04/21
Ryvu Therapeutics appoints Vatnak Vat-Ho as Chief Business Officer
Read more
08/04/21
Ryvu Announces Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Read more
18/03/21
Ryvu Therapeutics at BIO-Europe Spring
Read more
16/03/21
Ryvu Therapeutics reports financial results for 2020
Read more
16/03/21
Ryvu Therapeutics awarded in the Stock Exchange Company of the Year competition
Read more
11/03/21
Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2021 Virtual Annual Meeting
Read more
18/01/21
Ryvu Therapeutics project regarding Phase I/II clinical study of SEL120 (RVU 120) in solid tumors recommended for financing by NCBiR
Read more
07/01/21
Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland
Read more
04/01/21
Ryvu Therapeutics has submitted a new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors
Read more
21/12/20
"Dream with Ryvu" - a corporate movie by Ryvu Therapeutics
Read more
03/12/20
Ryvu Therapeutics publishes MNK1/2 kinase inhibitors research paper in the European Journal of Medicinal Chemistry
Read more
01/12/20
Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting
Read more
26/11/20
Solebury Trout Talks Podcast: Interview with Pawel Przewiezlikowski
Read more
23/11/20
Ryvu Therapeutics Appoints Kamil Sitarz as Chief Operating Officer and Member of the Management Board
Read more
19/11/20
Ryvu Therapeutics Reports Q3 2020 Financial Results
Read more
12/11/20
Ryvu Therapeutics at Jefferies Virtual London Healthcare Conference
Read more
19/10/20
Ryvu Therapeutics at BIO-Europe 2020
Read more
15/10/20
Ryvu Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting (SITC 2020)
Read more
16/09/20
First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia
Read more
15/09/20
Ryvu Therapeutics Reports 2020 Half-Year Financial Results
Read more
09/09/20
Ryvu Therapeutics to present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference
Read more
22/07/20
Ryvu Therapeutics raised over USD 36 million from its share issue
Read more
15/07/20
The share issue price in Ryvu Therapeutics public offering set at PLN 60
Read more
13/07/20
Ryvu Therapeutics shareholders have approved a new share issue. Book-building starts today.
Read more
10/06/20
Ryvu Therapeutics Reports First Quarter 2020 Financial Results
Read more
05/06/20
Ryvu Therapeutics signs a grant agreement for the development of targeted immuno-oncology therapy
Read more
03/06/20
NodThera, Ryvu spin-off company, secures £44.5million ($54.5million) Series B Financing
Read more
02/06/20
Ryvu Therapeutics has completed the construction of the R&D Center for Innovative Drugs
Read more
01/06/20
Ryvu Therapeutics at BIO Digital 2020
Read more
21/05/20
Ryvu Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference
Read more
18/05/20
Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2020 Virtual Annual Meeting II
Read more
14/05/20
Ryvu Therapeutics announces availability of abstracts regarding Phase 1/2 study of SEL120 and SEL24/MEN1703 accepted for presentation at 25th EHA Congress
Read more
16/04/20
Galapagos and Ryvu announce research collaboration
Read more
09/04/20
Ryvu Therapeutics Reports Annual 2019 Financial Results
Read more
31/03/20
Ryvu Therapeutics To Present At Solebury Trout Virtual Investor Conference
Read more
28/03/20
Ryvu Therapeutics receives Orphan Drug Designation from FDA for SEL120 to treat Acute Myeloid Leukemia
Read more
18/03/20
Successful Completion of Phase I Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia
Read more
17/03/20
Ryvu Therapeutics at BIO-Europe Spring 2020
Read more
05/03/20
Ryvu Therapeutics to Present at the 32nd Annual ROTH Conference
Read more
26/02/20
Ryvu Therapeutics signs a grant agreement for the development of targeted oncology therapies based on the synthetic lethality concept
Read more
20/01/20
Ryvu Therapeutics scientists as co-authors of Merck poster presentation on HIF-2alpha inhibitors
Read more
17/01/20
Ryvu Therapeutics together with scientists from the Jagiellonian University publish a synthetic lethality research paper in Biomolecules
Read more
06/11/19
Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting
Read more
06/11/19
Ryvu Therapeutics Reports Third Quarter 2019 Financial Results
Read more
05/11/19
Ryvu Therapeutics to Present at BIO-Europe 2019
Read more
14/10/19
Ryvu Therapeutics Appoints Chief Medical Officer Setareh Shamsili, M.D., Ph.D., to Executive Management Board
Read more
03/10/19
Ryvu Therapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)
Read more
01/10/19
Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland
Read more
19/09/19
Ryvu Announces Shareholder Approval of Corporate Split and New Name of Ryvu Therapeutics for Oncology Development Company
Read more
06/09/19
Ryvu Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Read more
03/09/19
Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split into Two Separately Listed Companies to Proceed
Read more
25/07/19
Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer
Read more
24/07/19
Selvita to Present at Upcoming Conferences in September
Read more
16/05/19
Selvita announces availability of abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for presentation at 2019 ASCO Annual Meeting and 24th EHA Congress
Read more
13/05/19
Selvita to Present at the UBS 2019 Global Healthcare Conference in New York
Read more
17/04/19
Poster regarding Phase 1/2 study of SEL24/MEN1703 accepted for the ASCO 2019 Annual Meeting
Read more
04/04/19
Selvita to present at the 2019 HCW Global Life Sciences Conference in London
Read more
28/03/19
Selvita to Separate Oncology Therapeutics and Contract Research Business Units into Two Global Companies
Read more
26/03/19
Selvita Announces U.S. FDA Acceptance of Investigational New Drug Application to Commence Clinical Development of SEL120 in the Treatment of Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Read more
04/03/19
Selvita to Present Data from Multiple Oncology Programs at AACR 2019 Annual Meeting
Read more
02/01/19
Selvita to Present at Biotech Showcase 2019 in San Francisco
Read more
21/11/18
Selvita Announces Presentations on CDK8 Inhibitor SEL120 at the 60th American Society of Hematology Annual Meeting
Read more
08/11/18
Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Read more
31/10/18
Selvita to present new data from its oncology programs at the upcoming SITC 2018
Read more
03/10/18
Selvita presents new data from SEL120 program during Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice
Read more
03/09/18
Selvita presents at the 25th Annual BioCentury NewsMakers in the Biotech Industry
Read more
27/08/18
Selvita to present new data from its oncology programs at the 6th Annual Immuno-Oncology Summit
Read more
26/04/18
Institute of Hematology and Transfusion Medicine and Selvita publish joint research results on SEL24 potential in Chronic Lymphocytic Leukemia
Read more
16/04/18
Selvita publishes research results on SEL24 in Oncotarget
Read more
06/04/18
Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2018
Read more
16/02/18
Selvita Announces Successful Completion of $41 M Book Building
Read more
16/12/17
FDA lifts Clinical Hold on Selvita’s Phase I/II Clinical Trial with SEL24 in AML
Read more
17/10/17
Selvita researchers and academic collaborators demonstrate the potential of MNK1/2 kinase inhibitors in the treatment of c-Kit positive melanomas
Read more
07/10/17
Selvita Announces Full Clinical Hold on Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia
Read more
03/10/17
Selvita and Menarini present together at the European Business Development Conference
Read more
08/08/17
Selvita and The Leukemia & Lymphoma Society Announce Partnership to Advance SEL120 into Phase I for AML Patients
Read more
13/07/17
Institute of Hematology and Transfusion Medicine and Selvita publish joint research results in SEL24 project
Read more
06/06/17
Selvita presents at 18th Drug Discovery Summit in Berlin
Read more
07/04/17
Selvita researchers publish new paper on CDK8 inhibitor SEL120 in Oncotarget
Read more
28/03/17
Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24
Read more
17/03/17
Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia
Read more
13/03/17
Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2017
Read more
13/02/17
Selvita researchers publish MNK inhibitors review in Current Medicinal Chemistry
Read more
16/12/16
Selvita to present at Biotech Showcase 2017 in San Francisco
Read more
30/11/16
Selvita presents posters at 2016 EORTC-NCI-AACR Symposium
Read more
18/08/16
FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML
Read more
18/08/16
FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML
Read more
28/07/16
Epidarex Capital Creates Nodthera Limite
Read more
06/06/16
Selvita epigenetic project is the first Polish drug target program selected by EU Lead Factory
Read more
01/02/16
Selvita will present at the 18th Annual BIO CEO & Investor Conference 2016
Read more
10/12/15
Selvita wins the European Rising Star Award
Read more
25/11/15
The most recent data from Selvita’s SEL24 to be presented at the 57th ASH Annual Meeting & Exposition
Read more
02/11/15
Merck and Selvita Announce Drug Discovery Collaboration
Read more
24/09/15
Selvita launches new company – bioinformatics and personalized medicine focused Ardigen
Read more
22/09/15
H3 Biomedicine and Selvita Extend Precision Cancer Medicines Collaboration
Read more
07/05/15
Selvita receives the Economic Award of the President of Poland
Read more
31/03/15
Selvita initiates IND-enabling Studies for its first-in-class PIM/FLT3 inhibitor
Read more
07/11/14
Felicitex Therapeutics and Selvita initiate strategic collaboration to target cancer quiescence
Read more
26/08/14
Selvita and H3 Biomedicine will present at the Drug Discovery USA Congress 2014
Read more
08/08/14
New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014
Read more

29/11/23
Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Read more

07/11/24
Ryvu Therapeutics Reports 2024 Q3 Financial Results and Provides Corporate Update
Read more
29/10/24
Ryvu Therapeutics to Collaborate with nCage Therapeutics on the Development of a Next-Generation ADC Platform
Read more
23/10/24
Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium
Read more
09/10/24
Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium
Read more
23/09/24
Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit
Read more
19/09/24
Ryvu Therapeutics Announces Dosing of the First Patient in the REMARK Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Read more
11/09/24
Ryvu Therapeutics Reports 2024 Half-Year Financial Results and Provides Corporate Update
Read more
14/06/24
Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress
Read more
15/05/24
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
Read more
14/05/24
Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress
Read more
10/04/24
Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
Read more
13/03/24
Ryvu Therapeutics Summarizes 2023 Fiscal Year and Provides Corporate Update
Read more
06/03/24
Ryvu Therapeutics Announces Disbursement of First Tranche of EUR 8 Million Venture Debt from the European Investment Bank  
Read more
06/03/24
Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
Read more
14/02/24
Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS
Read more
31/01/24
Ryvu Announces Dosing of the First Patient in the RIVER-81 Phase II Study of RVU120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory AML
Read more
04/01/24
Ryvu Therapeutics participates in the upcoming 13th Annual LifeSci Partners Corporate Access Event
Read more

11/12/23
Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting
Read more
07/12/23
Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023
Read more
02/11/23
Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting
Read more
23/10/23
Ryvu Therapeutics provides an update on the progress of RVU120 Phase I studies in patients with solid tumors and AML/HR-MDS, and presents the updated development plan for RVU120
Read more
20/10/23
Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes (LR-MDS)
Read more
16/10/23
Ryvu Therapeutics Presents Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Read more
04/10/23
Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Read more
14/09/23
Ryvu Therapeutics’ Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL)
Read more
13/09/23
Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update
Read more
11/09/23
Ryvu Therapeutics to Participate in the 31st Congress of the Polish Society of Hematology and Transfusion Medicine
Read more
04/08/23
Ryvu Therapeutics Announces Signing Two Agreements with Fortrea to Operationally Execute Phase II Clinical Trials of RVU120 in Hematology
Read more
31/07/23
Ryvu Therapeutics enters into a PLN 62.3 million financing agreement with the Medical Research Agency to conduct a Phase II clinical trial of RVU120 in combination therapy
Read more
31/07/23
Ryvu Therapeutics Announces Entering into Agreement in the Area of Securing Venetoclax Supply Chain for RVU120 Phase II Clinical Trial in Combination Therapy in Hematology
Read more
14/07/23
Ryvu Therapeutics enters into two agreements with Clinscience, part of the NEUCA Group, in the area of data management and biostatistics for RVU120 Phase II clinical trials in hematology
Read more
06/07/23
Ryvu Therapeutics enters into two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials
Read more
09/06/23
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress
Read more
16/05/23
Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Read more
11/05/23
Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress
Read more
24/03/23
Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Read more
15/03/23
Ryvu Therapeutics Named the Stock Exchange Company of the Year
Read more
05/01/23
Ryvu Therapeutics to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel and 12th Annual LifeSci Partners Corporate Access Event
Read more

22/12/22
Ryvu Therapeutics announces closing of equity offering with gross proceeds over PLN 250 million
Read more
11/12/22
Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting
Read more
08/12/22
Ryvu Therapeutics initiates public offering of shares
Read more
30/11/22
BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno Modulatory Small Molecule Candidates
Read more
23/11/22
Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Read more
03/11/22
Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting
Read more
26/10/22
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
Read more
12/10/22
Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
Read more
28/09/22
Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update
Read more
19/08/22
Ryvu Therapeutics presents its Development Plans for 2022-2024, aims to accelerate its mission
Read more
17/08/22
EIB to support Ryvu Therapeutics’ discovery, research and development of new cancer treatments with €22 million
Read more
26/07/22
Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board
Read more
07/07/22
Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
Read more
10/06/22
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress
Read more
06/06/22
Ryvu Therapeutics to Host Key Opinion Leader Webinar on RVU120 for the Treatment of Hematological Malignancies and Solid Tumors
Read more
19/05/22
Ryvu Therapeutics to Participate in Upcoming Investor Conferences
Read more
18/05/22
Ryvu Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Read more
12/05/22
Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association Congress. Partner Menarini Group to present clinical poster on SEL24 (MEN1703).
Read more
27/04/22
Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Read more
11/04/22
Ryvu Therapeutics Announces Presentations at the AACR 2022 Annual Meeting
Read more
15/03/22
Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Read more
08/03/22
Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting
Read more
17/01/22
Ryvu Therapeutics appoints Hendrik Nogai, M.D. as Chief Medical Officer
Read more
03/01/22
Ryvu Therapeutics to participate in the LifeSci Partners 11th Annual Corporate Access Event and H.C. Wainwright Bioconnect Conference
Read more

14/12/21
Ryvu announces option to license inflammation program exercised by Galapagos NV
Read more
13/12/21
Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology Annual Meeting and the 44th San Antonio Breast Cancer Symposium
Read more
10/11/21
Ryvu Therapeutics Reports Q3 2021 Financial Results
Read more
09/11/21
Ryvu Therapeutics to Highlight HPK1 and STING Programs at the Upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Read more
04/11/21
Ryvu Therapeutics & Collaborators to Present Clinical and Translational Data from RVU120 and SEL24/MEN1703 at the 63rd ASH Annual Meeting & Exposition and the 44th Annual SABCS
Read more
07/10/21
Ryvu Therapeutics co-runs Drug Discovery and Development MSc degree, at the Faculty of Pharmacy, Jagiellonian University
Read more
08/09/21
Ryvu Therapeutics Reports 2021 Half-Year Financial Results
Read more
25/08/21
Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors and CMO Transition
Read more
18/08/21
Ryvu Therapeutics publishes MCT4 inhibitors research paper in the Journal of Medicinal Chemistry
Read more
03/08/21
Ryvu Therapeutics to participate in upcoming global investor conferences
Read more
14/07/21
FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Read more
11/06/21
Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual EHA Congress. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini.
Read more
10/06/21
Representatives of the Ministry of Economic Development, Labour and Technology visited Ryvu Therapeutics
Read more
10/06/21
Ryvu Therapeutics among the founding members of 30% Club Poland
Read more
09/06/21
Discussion On Ryvu Data Presented at EHA 2021 – Conference Call
Read more
02/06/21
Synthetic lethality in cancer treatment – Ryvu Therapeutics seminar
Read more
01/06/21
SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021
Read more
28/05/21
Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland
Read more
18/05/21
Ryvu Therapeutics announces participation in the UBS 2021 Global Healthcare Virtual Conference and the Erste Group Innovation Conference 2021
Read more
14/05/21
Ryvu Therapeutics presents at STING- & TLR-Targeting Therapies Summit
Read more
12/05/21
Ryvu Therapeutics to Present Clinical and Translational Data from RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. New clinical abstract on SEL24(MEN1703) also available.
Read more
12/05/21
Ryvu Therapeutics Reports First Quarter 2021 Financial Results
Read more
26/04/21
Ryvu Therapeutics appoints Vatnak Vat-Ho as Chief Business Officer
Read more
08/04/21
Ryvu Announces Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Read more
18/03/21
Ryvu Therapeutics at BIO-Europe Spring
Read more
16/03/21
Ryvu Therapeutics reports financial results for 2020
Read more
16/03/21
Ryvu Therapeutics awarded in the Stock Exchange Company of the Year competition
Read more
11/03/21
Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2021 Virtual Annual Meeting
Read more
18/01/21
Ryvu Therapeutics project regarding Phase I/II clinical study of SEL120 (RVU 120) in solid tumors recommended for financing by NCBiR
Read more
07/01/21
Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland
Read more
04/01/21
Ryvu Therapeutics has submitted a new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors
Read more

21/12/20
"Dream with Ryvu" - a corporate movie by Ryvu Therapeutics
Read more
03/12/20
Ryvu Therapeutics publishes MNK1/2 kinase inhibitors research paper in the European Journal of Medicinal Chemistry
Read more
01/12/20
Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting
Read more
26/11/20
Solebury Trout Talks Podcast: Interview with Pawel Przewiezlikowski
Read more
23/11/20
Ryvu Therapeutics Appoints Kamil Sitarz as Chief Operating Officer and Member of the Management Board
Read more
19/11/20
Ryvu Therapeutics Reports Q3 2020 Financial Results
Read more
12/11/20
Ryvu Therapeutics at Jefferies Virtual London Healthcare Conference
Read more
19/10/20
Ryvu Therapeutics at BIO-Europe 2020
Read more
15/10/20
Ryvu Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting (SITC 2020)
Read more
16/09/20
First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia
Read more
15/09/20
Ryvu Therapeutics Reports 2020 Half-Year Financial Results
Read more
09/09/20
Ryvu Therapeutics to present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference
Read more
22/07/20
Ryvu Therapeutics raised over USD 36 million from its share issue
Read more
15/07/20
The share issue price in Ryvu Therapeutics public offering set at PLN 60
Read more
13/07/20
Ryvu Therapeutics shareholders have approved a new share issue. Book-building starts today.
Read more
10/06/20
Ryvu Therapeutics Reports First Quarter 2020 Financial Results
Read more
05/06/20
Ryvu Therapeutics signs a grant agreement for the development of targeted immuno-oncology therapy
Read more
03/06/20
NodThera, Ryvu spin-off company, secures £44.5million ($54.5million) Series B Financing
Read more
02/06/20
Ryvu Therapeutics has completed the construction of the R&D Center for Innovative Drugs
Read more
01/06/20
Ryvu Therapeutics at BIO Digital 2020
Read more
21/05/20
Ryvu Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference
Read more
18/05/20
Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2020 Virtual Annual Meeting II
Read more
14/05/20
Ryvu Therapeutics announces availability of abstracts regarding Phase 1/2 study of SEL120 and SEL24/MEN1703 accepted for presentation at 25th EHA Congress
Read more
16/04/20
Galapagos and Ryvu announce research collaboration
Read more
09/04/20
Ryvu Therapeutics Reports Annual 2019 Financial Results
Read more
31/03/20
Ryvu Therapeutics To Present At Solebury Trout Virtual Investor Conference
Read more
28/03/20
Ryvu Therapeutics receives Orphan Drug Designation from FDA for SEL120 to treat Acute Myeloid Leukemia
Read more
18/03/20
Successful Completion of Phase I Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia
Read more
17/03/20
Ryvu Therapeutics at BIO-Europe Spring 2020
Read more
05/03/20
Ryvu Therapeutics to Present at the 32nd Annual ROTH Conference
Read more
26/02/20
Ryvu Therapeutics signs a grant agreement for the development of targeted oncology therapies based on the synthetic lethality concept
Read more
20/01/20
Ryvu Therapeutics scientists as co-authors of Merck poster presentation on HIF-2alpha inhibitors
Read more
17/01/20
Ryvu Therapeutics together with scientists from the Jagiellonian University publish a synthetic lethality research paper in Biomolecules
Read more

06/11/19
Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting
Read more
06/11/19
Ryvu Therapeutics Reports Third Quarter 2019 Financial Results
Read more
05/11/19
Ryvu Therapeutics to Present at BIO-Europe 2019
Read more
14/10/19
Ryvu Therapeutics Appoints Chief Medical Officer Setareh Shamsili, M.D., Ph.D., to Executive Management Board
Read more
03/10/19
Ryvu Therapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)
Read more
01/10/19
Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland
Read more
19/09/19
Ryvu Announces Shareholder Approval of Corporate Split and New Name of Ryvu Therapeutics for Oncology Development Company
Read more
06/09/19
Ryvu Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Read more
03/09/19
Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split into Two Separately Listed Companies to Proceed
Read more
25/07/19
Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer
Read more
24/07/19
Selvita to Present at Upcoming Conferences in September
Read more
16/05/19
Selvita announces availability of abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for presentation at 2019 ASCO Annual Meeting and 24th EHA Congress
Read more
13/05/19
Selvita to Present at the UBS 2019 Global Healthcare Conference in New York
Read more
17/04/19
Poster regarding Phase 1/2 study of SEL24/MEN1703 accepted for the ASCO 2019 Annual Meeting
Read more
04/04/19
Selvita to present at the 2019 HCW Global Life Sciences Conference in London
Read more
28/03/19
Selvita to Separate Oncology Therapeutics and Contract Research Business Units into Two Global Companies
Read more
26/03/19
Selvita Announces U.S. FDA Acceptance of Investigational New Drug Application to Commence Clinical Development of SEL120 in the Treatment of Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Read more
04/03/19
Selvita to Present Data from Multiple Oncology Programs at AACR 2019 Annual Meeting
Read more
02/01/19
Selvita to Present at Biotech Showcase 2019 in San Francisco
Read more
08/08/14
New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014
Read more

21/11/18
Selvita Announces Presentations on CDK8 Inhibitor SEL120 at the 60th American Society of Hematology Annual Meeting
Read more
08/11/18
Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Read more
31/10/18
Selvita to present new data from its oncology programs at the upcoming SITC 2018
Read more
03/10/18
Selvita presents new data from SEL120 program during Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice
Read more
03/09/18
Selvita presents at the 25th Annual BioCentury NewsMakers in the Biotech Industry
Read more
27/08/18
Selvita to present new data from its oncology programs at the 6th Annual Immuno-Oncology Summit
Read more
26/04/18
Institute of Hematology and Transfusion Medicine and Selvita publish joint research results on SEL24 potential in Chronic Lymphocytic Leukemia
Read more
16/04/18
Selvita publishes research results on SEL24 in Oncotarget
Read more
06/04/18
Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2018
Read more
16/02/18
Selvita Announces Successful Completion of $41 M Book Building
Read more

16/12/17
FDA lifts Clinical Hold on Selvita’s Phase I/II Clinical Trial with SEL24 in AML
Read more
17/10/17
Selvita researchers and academic collaborators demonstrate the potential of MNK1/2 kinase inhibitors in the treatment of c-Kit positive melanomas
Read more
07/10/17
Selvita Announces Full Clinical Hold on Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia
Read more
03/10/17
Selvita and Menarini present together at the European Business Development Conference
Read more
08/08/17
Selvita and The Leukemia & Lymphoma Society Announce Partnership to Advance SEL120 into Phase I for AML Patients
Read more
13/07/17
Institute of Hematology and Transfusion Medicine and Selvita publish joint research results in SEL24 project
Read more
06/06/17
Selvita presents at 18th Drug Discovery Summit in Berlin
Read more
07/04/17
Selvita researchers publish new paper on CDK8 inhibitor SEL120 in Oncotarget
Read more
28/03/17
Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24
Read more
17/03/17
Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia
Read more
13/03/17
Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2017
Read more
13/02/17
Selvita researchers publish MNK inhibitors review in Current Medicinal Chemistry
Read more

16/12/16
Selvita to present at Biotech Showcase 2017 in San Francisco
Read more
30/11/16
Selvita presents posters at 2016 EORTC-NCI-AACR Symposium
Read more
18/08/16
FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML
Read more
18/08/16
FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML
Read more
28/07/16
Epidarex Capital Creates Nodthera Limite
Read more
06/06/16
Selvita epigenetic project is the first Polish drug target program selected by EU Lead Factory
Read more
01/02/16
Selvita will present at the 18th Annual BIO CEO & Investor Conference 2016
Read more

10/12/15
Selvita wins the European Rising Star Award
Read more
25/11/15
The most recent data from Selvita’s SEL24 to be presented at the 57th ASH Annual Meeting & Exposition
Read more
02/11/15
Merck and Selvita Announce Drug Discovery Collaboration
Read more
24/09/15
Selvita launches new company – bioinformatics and personalized medicine focused Ardigen
Read more
22/09/15
H3 Biomedicine and Selvita Extend Precision Cancer Medicines Collaboration
Read more
07/05/15
Selvita receives the Economic Award of the President of Poland
Read more
31/03/15
Selvita initiates IND-enabling Studies for its first-in-class PIM/FLT3 inhibitor
Read more

07/11/14
Felicitex Therapeutics and Selvita initiate strategic collaboration to target cancer quiescence
Read more
26/08/14
Selvita and H3 Biomedicine will present at the Drug Discovery USA Congress 2014
Read more
08/08/14
New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014
Read more

Investors & Media

Ryvu Therapeutics Reports 2024 Q3 Financial Results and Provides Corporate Update

Ryvu Therapeutics to Collaborate with nCage Therapeutics on the Development of a Next-Generation ADC Platform

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics Announces Dosing of the First Patient in the REMARK Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Ryvu Therapeutics Reports 2024 Half-Year Financial Results and Provides Corporate Update

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update

Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Therapeutics Summarizes 2023 Fiscal Year and Provides Corporate Update

Ryvu Therapeutics Announces Disbursement of First Tranche of EUR 8 Million Venture Debt from the European Investment Bank

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Announces Dosing of the First Patient in the RIVER-81 Phase II Study of RVU120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory AML

Ryvu Therapeutics participates in the upcoming 13th Annual LifeSci Partners Corporate Access Event

Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023

Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics provides an update on the progress of RVU120 Phase I studies in patients with solid tumors and AML/HR-MDS, and presents the updated development plan for RVU120

Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes (LR-MDS)

Ryvu Therapeutics Presents Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Ryvu Therapeutics’ Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL)

Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update

Ryvu Therapeutics to Participate in the 31st Congress of the Polish Society of Hematology and Transfusion Medicine

Ryvu Therapeutics Announces Signing Two Agreements with Fortrea to Operationally Execute Phase II Clinical Trials of RVU120 in Hematology

Ryvu Therapeutics enters into a PLN 62.3 million financing agreement with the Medical Research Agency to conduct a Phase II clinical trial of RVU120 in combination therapy

Ryvu Therapeutics Announces Entering into Agreement in the Area of Securing Venetoclax Supply Chain for RVU120 Phase II Clinical Trial in Combination Therapy in Hematology

Ryvu Therapeutics enters into two agreements with Clinscience, part of the NEUCA Group, in the area of data management and biostatistics for RVU120 Phase II clinical trials in hematology

Ryvu Therapeutics enters into two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress

Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress

Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Ryvu Therapeutics Named the Stock Exchange Company of the Year

Ryvu Therapeutics to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel and 12th Annual LifeSci Partners Corporate Access Event

Ryvu Therapeutics announces closing of equity offering with gross proceeds over PLN 250 million

Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics initiates public offering of shares

BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno Modulatory Small Molecule Candidates

Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

Ryvu Therapeutics presents its Development Plans for 2022-2024, aims to accelerate its mission

EIB to support Ryvu Therapeutics’ discovery, research and development of new cancer treatments with €22 million

Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board

Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics to Host Key Opinion Leader Webinar on RVU120 for the Treatment of Hematological Malignancies and Solid Tumors

Ryvu Therapeutics to Participate in Upcoming Investor Conferences

Ryvu Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association Congress. Partner Menarini Group to present clinical poster on SEL24 (MEN1703).

Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Ryvu Therapeutics Announces Presentations at the AACR 2022 Annual Meeting

Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

Ryvu Therapeutics appoints Hendrik Nogai, M.D. as Chief Medical Officer

Ryvu Therapeutics to participate in the LifeSci Partners 11th Annual Corporate Access Event and H.C. Wainwright Bioconnect Conference

Ryvu announces option to license inflammation program exercised by Galapagos NV

Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology Annual Meeting and the 44th San Antonio Breast Cancer Symposium

Ryvu Therapeutics Reports Q3 2021 Financial Results

Ryvu Therapeutics to Highlight HPK1 and STING Programs at the Upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Ryvu Therapeutics & Collaborators to Present Clinical and Translational Data from RVU120 and SEL24/MEN1703 at the 63rd ASH Annual Meeting & Exposition and the 44th Annual SABCS

Ryvu Therapeutics co-runs Drug Discovery and Development MSc degree, at the Faculty of Pharmacy, Jagiellonian University

Ryvu Therapeutics Reports 2021 Half-Year Financial Results

Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors and CMO Transition

Ryvu Therapeutics publishes MCT4 inhibitors research paper in the Journal of Medicinal Chemistry

Ryvu Therapeutics to participate in upcoming global investor conferences

FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual EHA Congress. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini.

Representatives of the Ministry of Economic Development, Labour and Technology visited Ryvu Therapeutics

Ryvu Therapeutics among the founding members of 30% Club Poland

Discussion On Ryvu Data Presented at EHA 2021 – Conference Call

Ryvu Therapeutics Reports 2024 Q3 Financial Results and Provides Corporate Update

Ryvu Therapeutics to Collaborate with nCage Therapeutics on the Development of a Next-Generation ADC Platform

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics Announces Disbursement of First Tranche of EUR 8 Million Venture Debt from the European Investment Bank  

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology Annual Meeting and the 44th San Antonio Breast Cancer Symposium